EmbryoNet-AI
EmbryoNet-AI23About
Technology stack
detected 2026-07-07No comments yet. Be the first to share your take.
What does EmbryoNet-AI do?
EmbryoNet-AI is an ERC-funded research-to-commercialization project developing deep learning models for automated embryonic and organoid phenotyping. The platform enables faster, more accurate assessment of compound effects in drug discovery and toxicology studies, reducing dependence on animal models. The project is building a user-friendly web interface and collaborating with pharma partners to commercialize the technology.
How much funding has EmbryoNet-AI raised?
EmbryoNet-AI has raised a total of $150K in funding. The most recent round on record is Grant.
Where is EmbryoNet-AI headquartered?
EmbryoNet-AI is headquartered in Lisbon, Portugal.
When was EmbryoNet-AI founded?
EmbryoNet-AI was founded in 2025.
What industry does EmbryoNet-AI operate in?
EmbryoNet-AI operates in Biotech, Drug Discovery, AI, Medical Imaging, Toxicology, Embryology.
What is EmbryoNet-AI's revenue?
StartupHub estimates EmbryoNet-AI's annual revenue at $26K (range $4K to $67K, 29% confidence), based on comparable companies in the sector.
What is EmbryoNet-AI's valuation?
StartupHub estimates EmbryoNet-AI's effective valuation at $519K (range $375K to $900K, 23% confidence), based on comparable companies in the sector.